Improving radiation oncology through clinical audits: Introducing the IROCA project by Torras, Maria Glòria et al.
reports of practical oncology and radiotherapy 2 2 ( 2 0 1 7 ) 408–414
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Preliminary communication
Improving  radiation  oncology  through  clinical
audits: Introducing  the IROCA  project
Maria Glòria Torrasa,∗, Magdalena Fundowiczb, Luisa Aliste f,
Esther  Asensioa, Anna Maria Boladerasa, Josep Maria Borràs f,
Luísa  Carvalhoe, Carla Castroe, Letizia Deantoniod, Ewelina Konstantyb,
Marco Krengli d, Marta Kruszynab, Joana Lencart e, Miquel Maciàa,
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As radiotherapy practice and processes become more complex, the need to assure quality
control becomes ever greater. At present, no international consensus exists with regards to
the  optimal quality control indicators for radiotherapy; moreover, few clinical audits have
been  conducted in the field of radiotherapy. The present article describes the aims and
current status of the international IROCA “Improving Radiation Oncology Through Clini-
cal  Audits” project. The project has several important aims, including the selection of key
quality indicators, the design and implementation of an international audit, and the har-





primary aim is to improve the processes that directly impact clinical outcomes for patients.
The  experience gained from this initiative may serve as the basis for an internationally
accepted clinical audit model for radiotherapy.
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treatment, our prior experience, and because all participat-reports of practical oncology and 
.  Background
n recent decades, the effectiveness of radiotherapy has
ncreased considerably due to the advent of ever more  power-
ul, more  precise technologies, such as intensity-modulated
adiotherapy (IMRT). The use of more  sophisticated tech-
ologies has also increased the complexity of radiotherapy
elivery. As a result, every step in the radiotherapy process has
ecome more  demanding and multifaceted, requiring strict
ttention to detail to assure that the high doses of radiation are
elivered precisely to the treatment target. To ensure the qual-
ty of radiotherapy delivery and treatment, it is essential to
onitor the process carefully and systematically, with routine
nd frequent checks and assessments. However, the develop-
ent and implementation of quality control measures have
ot kept pace with the remarkable technological advances
chieved in recent years.1–4
A common approach to quality control in cancer care
nvolves the use of quality indicators. Ideally—given the wide
ariety of processes and techniques involved in treating dif-
erent types of cancer—these indicators should be specifically
esigned (or adapted to) each tumour type. In this sense, the
vailability of a set of internationally recognized and standard-
zed indicators to permit international comparisons among
adiotherapy centres would be highly desirable. Yet experience
n this area remains limited, with no consensus with regard to
he optimal indicators for radiotherapy.3 Indeed, although sev-
ral different groups3–7 have attempted to identify a core group
f quality indicators for radiotherapy, no widely-accepted or
nternationally-recognized core set of indicators is available at
resent.
While quality indicators are important to ensuring quality
ontrol, to be of any real value these indicators must be applied
o actual clinical practice—preferably by external evaluators.
his process, known as a clinical audit, provides an opportu-
ity to conduct an in-depth analysis of the procedures and
rocesses governing patient care. To date, such clinical audits
ave been used only sparingly in radiotherapy,2,3,8 although
easures to increase their use have been taken, including a
uropean Union directive requiring their use.4
Interest in developing and implementing a system of qual-
ty standards in radiotherapy has increased greatly in recent
ears.9–12 Nevertheless, only a limited number of clinical
udits, including one by our group,2 have been conducted to
ate.2,13–15 It is in this context that the multi-institutional,
nternational IROCA (Improving quality in Radiation Oncology
hrough Clinical Audits;  www.iroca.eu) project was born. The
im of this project is to compare radiotherapy processes
mong participating institutions [the Wielkopolskie Cen-
rum Onkologii (WCO) in Poznan, Poland; the Institut Català
’Oncologia (ICO) in L’Hospitalet (Barcelona), Spain; the Insti-
uto Português de Oncologia (IPO) in Porto, Portugal; and the
niversità degli Studi del Piemonte Orientale (UNIUPO) in
ovara, Italy] using a core set of quality indicators. To our
nowledge, this is the first project of its kind and scope.
In the present paper, we provide an overview of this
nternational project, which involves the design and imple-
entation of a clinical audit to assess adherence to a set of
ore quality indicators to evaluate departmental/institutionaltherapy 2 2 ( 2 0 1 7 ) 408–414 409
structure, radiotherapy processes and procedures, and clini-
cal outcomes among the five participating institutions. The
overall aim of the project is to improve quality and safety in
radiation oncology by promoting adherence to quality indica-
tors and by harmonizing radiotherapy processes among the
participating institutions. Ultimately, the main objective is to
improve clinical outcomes for patients. The approach used
in this project to harmonize radiotherapy processes among
different institutions may serve to promote a greater use of
clinical audits in radiotherapy in Europe.
2.  Methods  &  discussion
This study was modelled on two previous studies. The first
was performed jointly by the ICO (Catalan Institute of Oncol-
ogy) and the WCO  (Greater Poland Cancer Centre), with results
published in 2014.2 In that study, which was conducted—in
part—to generate more  practical experience in quality control,
the clinical audit assessed adherence to seven quality indica-
tors for preoperative rectal cancer treatment. This experience
was invaluable, both in improving key elements of care at the
audited institutions, and in learning about how to develop
and conduct a comprehensive clinical audit, a challenging and
highly complex task. In addition, in the year 2015, the ICO
(Catalonia, Spain) performed an in-house clinical audit among
their three radiotherapy centres (in Badalona, L’Hospitalet,
and Girona). Results from that study have not yet been pub-
lished. Nevertheless, the combined experience of these two
previous studies has helped to guide us in developing the
model described here.
2.1.  Organization  of  the  project
A Steering Committee (SC) consisting of senior members of
the IROCA project was formed to guide the development of
this project. The IROCA members held a series of meetings
to establish the aims and protocol for the study, including
selection of the target cancer types for the audit. After a care-
ful review of the literature and based on previous experience,
the committee selected the most appropriate quality control
indicators for those tumour sites and for general radiothe-
rapy processes. A Technical Committee (TC) was constituted
to perform the statistical analysis and to develop the reports.
A detailed study protocol, including the questionnaire and
all other relevant data, has been developed. The project’s key
aims are summarized in Table 1.
2.2.  Cancer  types  for  evaluation
Two cancer sites, prostate (ICD-9:185.9 and ICD10: C61.9) and
rectal cancer (ICD-9: 154.1; ICD-10: C20.9) were selected for the
clinical audit.
These specific cancer types were chosen due to their high
incidence rate,16 the relevant role of radiotherapy in theiring institutions treat large numbers of patients for these two
cancer types. In the case of rectal cancer, the high incidence
and mortality rates associated with this cancer make it an
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Table 1 – Improving clinical outcomes of radiotherapy
through step-by step standardization of key elements in
clinical practice at participating institutions.
1. Identify key aspects within the radiotherapy process that
impact clinical outcomes and treatment efficiency.
2. Determine the most relevant indicators to measure these
key aspects.
3. Design a clinical audit procedure to determine adherence to
these indicators at participating institutions.
4. Identify the areas amenable to standardization of the
following:
•treatment approach
•treatment planning and execution
•reporting the outcomes (results and side effects)
•patient comfort
•healthcare provider accountability and reliability
Table 2 – General indicators.
1. Existence of technical protocols for treatment
2. Existence of departmental clinical meetings
3. Existence of departmental technical meetings
4. Existence of an action protocol in case of unplanned
treatment interruptions
5. Existence of quality control protocol for treatment-related
imaging
6. Existence of an informed consent form specific to each
cancer type and/or technique
7. Existence of a protocol for irradiating patients with
ICD/pacemaker (PM)
8. Existence of tumour-specific treatment guidelines
9. Number of articles published in indexed journals by
radiation oncology, physics and radiation biology staff
members
10. Number of published articles in which either the three first
authors or the last author is a member of the team
11. Total impact factor of the articles published during the year
by staff involved in radiation oncology, physics and radiation
biology in which either three first authors or the last author
is a member of the team
12. Number of projects submitted for funding to national or
international bodies/institutions excluding trials financed by
pharmaceutical companies
13. Number of projects approved for funding to national or
international bodies/institutions excluding trials financed by
pharmaceutical companies
14. Participation in European Union grant
15. Leadership of European Union grant
16. Number of clinical trials specific to radiation oncology and
% of patients included in these trials
17. Number of patients included in clinical trials involving
radiotherapy treatment and radiatio oncologist is primary
investigator
18. Existence of patient satisfaction survey
19. % of patients who completed satisfaction survey
20. Patients treated per year
21. Patients treated per accelerator
22. Up/down time of the accelerators (according to
recommended calculation formula; otherwise, the specific
formula should be provided)•efficient use of resources
5. Develop a minimum dataset for benchmarking.
ideal candidate for auditing due to the large impact even small
improvements in cancer care could have on clinical outcomes.
2.3.  Target  population  and  sample  selection
Patients diagnosed with either prostate or rectal cancer who
underwent curative-intent radiotherapy during the study
inclusion period (calendar year 2014). Patients who did not
receive neoadjuvant radiotherapy and those with recurrent
disease will be excluded. To minimize the risk of bias, patients
will be randomly selected as follows: all patients who meet
the inclusion criteria will be assigned an identification num-
ber; next, a separate register will be created for these eligible
patients and a computer program will randomly select 60 clin-
ical cases per tumour site. All patients who meet the inclusion
criteria will be included in the audit, with a minimum require-
ment of 40 patients per tumour site.
2.4.  Selection  of  quality  indicators,  standards  and
questionnaires
After a review of the available indicators, including those pro-
posed by other authors,3 those used in our previous study,2
and the indicators used in the ICO study, we  selected a set
of clinical indicators applicable to all radiotherapy processes
(Table 2), plus indicators specific to prostate and rectal cancer
radiotherapy (Tables 3 and 4).
After selection of the specific indicators, we  proceeded
to develop three questionnaires, including a general ques-
tionnaire, to assess all the variables relevant to the quality
indicators to measure overall performance of the radiotherapy
process. The aggregate data needed to complete the general
questionnaire will be obtained directly from the radiotherapy
department and include the following key dimensions:
1. Organization (protocols, sessions, tumour boards)
2. Radiotherapy equipment
3. Work team
4. Research (publications, projects, and clinical trials)
5. Radiotherapy activity
6. Patient experience23. Average number of patients treated per hour per accelerator
24. % of reports completed within 2 months of treatment
finalization
7. Quality of care (safety, efficiency, accessibility, and treat-
ments delays)
The other two questionnaires are specific to the two cancer
types (prostate and rectal cancer) and are designed to assess
the core indicators for each tumour type. All data (>100 vari-
ables) required to complete the questionnaire will be obtained
from clinical records.
The key dimensions of these two questionnaires are as fol-
lows:
1. Diagnostic phase: multidisciplinary tumour board assess-
ment, clinical profile (stage, etc.), diagnostic tests, and
treatment delays.
2. Treatment phase: treatment planned and performed;
radiotherapy dose, fraction and duration (prescribed versus
performed); quality of care; adjuvant treatments
3. Clinical results and follow up phase: treatment-related
side-effects; clinical status (recurrence; mortality);
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Table 3 – Prostate indicators.
1. % of patients evaluated in the clinical session in the
Radiation Oncology (RO) department before treatment
2. % of patients with stratification (including PSA, Gleason,
TNM)
3. % of patients with MRI staging
4. % of patients presented to the tumour board
5. % of patients with tumour localized with fiducial markers
6. % of patients with tumour localized by CBCT
7. % of patients with tumour localized by ultrasound
8. % of patients who experience an interruption in treatment
9. % of patients completing treatment in the prescribed time
10. % of high risk patients receiving long-term hormonotherapy
11. % of high risk patients receiving boost brachytherapy
12. Time elapsed between first visit at RO department and
initiation of any type of treatment
13. Time elapsed between first visit at RO department and start
of radiotherapy (EBRT, BRT)
14. Time elapses between CT simulation and start of
radiotherapy (EBRT, BRT)
15. % of patients treated using new technologies (IMRT)
16. % of patients treated using new technologies (VMAT)
17. % of patients treated using new technologies (SBRT)
18. % of EBRT sessions with imaging controls performed during
the treatment (kV, MV, CBCT, MVCT)
19. % of patients with rectal mucositis (grade 2 or 3) (less than
6 months)
20. % of patients with rectal mucositis (grade 2 or 3) (more than
6 months)
21. % of patients with cystitis-urethritis (grade 2 or 3) (less than
6 months)
22. % of patients with cystitis-urethritis (grade 2 or 3) (more
than 6 months)
23. Biochemical survival
24. Regular follow-up after the treatment (Yes/No)






















Table 4 – Rectal indicators.
1. % of patients evaluated in the clinical session in the
Radiation Oncology (RO) department before treatment
2. % of patients with TNM staging
3. % of patients with MRI staging
4. % of patients presented to the tumour board
5. % of patients with tumour localized with CBCT-IGRT
6. % of patients with tumour localized with kV-IGRT
7. % of patients completing treatment in the prescribed time
8. % of patients receiving concomitant chemotherapy
9. % of patients prescribed long course radiotherapy
10. % of patients prescribed short course radiotherapy
11. % of patients receiving intraoperative radiotherapy (IORT)
12. Time elapsed between biopsy and first consultation at RO
department
13. Time elapsed between first visit at RO department and start
of radiotherapy
14. Time elapsed between CT simulation and beginning of
radiotherapy
15. % of patients treated using new technologies (IMRT)
16. % of patients treated using new technologies (VMAT)
17. % of EBRT sessions with imaging controls performed during
the treatment (kV, MV, CBCT, MVCT)
18. % of patients with rectitis (grade 2 or 3) (less than 6 months)
19. % of patients with rectitis (grade 2 or 3) (more than 6
months)
20. % of patients with cystitis-urethritis (grade 2 or 3) (less than
6 months)




domly selected from the sample) for each pathology while
jointly (i.e., the local auditor and the SC specialists) com-The questionnaires were primarily based on those pre-
iously used in the aforementioned ICO study (data not
ublished), which in turn were based on the questionnaires
sed in the Fundowicz study,2 and the International Atomic
nergy Association (IAEA) QUATRO model.17 We  elected to
se an online questionnaire due to the numerous advantages:
inimization of registration data errors, data centralization in
 single database accessible to participant centres and located
t ICO servers), and centralization of the statistical analyses
ICO), which will be performed with the SPSS statistical soft-
are (IBM, NY, USA).
.5.  Implementation  of  the  clinical  audit
he pilot study is planned for September, 2016 at the WCO
n Poznan, Poland. The pilot audit will serve as a model for
uture audits once completed. Here, we  describe the current
lans for the pilot audit, but based on our actual experience,
e may need to modify the timing and structure of the official
linical audit (tentatively planned for the 4th quarter of 2016).
fter the first pilot audit has been completed, a meeting will
e held to discuss any issues that have arisen and to correct
nd/or improve the auditing procedure. This will involve all
embers of the participating institutions.24. Regular follow-up after treatment (yes/no)
25. Regular follow-up during treatment (yes/no)
2.6.  Audit  schedule
A checklist will be created to organize the audit program and to
ensure coverage of all relevant topics. The working language
of the audit is English. The clinical audit will be performed
as follows: a) audit preparation (appointment of auditing
team, review of the background information prepared by the
institution to be audited, and preparation of the audit pro-
gram); b) entrance briefing: to introduce the auditors to various
staff members and to discuss the methods, objectives and
details of the audit; and c) assessment: on-site clinical audit.
2.6.1.  Two-day  pre-audit  training  and  verifications
The role of the specialists from the SC is crucial to the success-
ful outcome of the audit. For this reason, before the Local Team
(LT) begins to conduct the actual clinical audit, two specialists
from the SC team will meet with the LT (i.e., the clinical audi-
tor[s] and local leaders) for 2 days for training and verifications
to assure that all procedures are clear and that everything is
in place to properly conduct the audit.
Specific tasks during this two-day pre-audit period include:
• Assure access to the database
• Train the LT and verify the forms by reviewing 2 cases (ran-pleting the online questionnaires.
d rad412  reports of practical oncology an
• Confirm the accuracy of the data reported on the general
questionnaire (which contains details about the centre and
procedures). This questionnaire will be sent to the audited
centre well in advance of the audit.
During this two-day period, in addition to the aforemen-
tioned training and verifications, the SC team will interview
staff members from the institution about work practices and
approaches, inspect the facilities, and review all procedures
and relevant documentation (including the treatment records
of rectal and prostate cancer patients included in the study). In
addition, the auditors will directly observe the practical imple-
mentation of working procedures during the audit, including
as many  aspects of the patient treatment process (initial
patient examination, diagnosis, evaluation, staging, treatment
planning and delivery, and follow up) as feasible.
The medical records are to be reviewed by an ‘external
team’ (i.e., not dependent on the departmental heads) to
assure a bias-free (“neutral”) assessment of the data collected.
The audit teams will consist of at least one auditor, who should
be a nurse (or other qualified health care professional) spe-
cialized in health information management with >two years
of experience in clinical reviews (ISO or similar). It is strongly
recommended that the audit not be performed by a radiation
oncologist or medical physicist from the audited departments.
2.6.2.  Clinical  audit
After the two-day training and verification period, the local
team will carry out the clinical audit during which the audi-
tor(s) will review 40 randomly-selected cases per pathology
and complete a relevant questionnaire. Based on our previous
experience, we  estimate that the time required to perform the
audit will be approximately 20–30 min  per case. For this rea-
son, the local auditor(s) will need at least 2 weeks to audit all
80 cases.
After the data collection has been completed, the TC will
carry out a quality control analysis on the data and then con-
duct the statistical analysis. Once this has been performed, an
exit briefing will be organized to provide the host institution
with preliminary feedback.
The estimated duration of the entire process, including
review of clinical records and statistical analysis, is approx-
imately 45 days, as follows: 15 days to review the medical
records and 30 days for quality control of the data, statistical
analysis, and preparation of initial results. Technical support
(video conference) will be available during this phase should
any doubts arise.
2.7.  Expected  results  and  study  limitations
The IROCA project was created to promote quality and effi-
cacy in radiotherapy. The project will compare radiotherapy
processes among the member institutions using a core set of
quality indicators selected by consensus among the partici-
pating institutions. The main aim of this study is to determine
institutional adherence to the consensus standards jointly
established by the project members in accordance with the
best available evidence, and to compare adherence to these
standards across the various institutions to identify best prac-
tices. Our broader aims are to develop a clinical audit modeliotherapy 2 2 ( 2 0 1 7 ) 408–414
for radiotherapy that can be easily adopted by other centres
around the world, thus expanding the use of clinical audits to
improve the quality of care. To our knowledge, this is the first
project of its kind and scope.
There can be little doubt about the importance of qual-
ity control in any area of medicine. However, in the area of
radiotherapy, already considered among the safest areas, the
use of high-dose ionizing radiation is important to moni-
tor quality because of the risk of patient harm.18 Moreover,
modern radiotherapy requires numerous procedures and pro-
cesses involving a large number of health care professionals,
including radiation oncologists, medical physicists, other
physicians, nurses and technologists. As a result, quality con-
trol is essential to guarantee optimal quality throughout this
complex process.
The importance of performing a clinical audit to ensure
adherence to treatment protocols in medical care cannot be
understated,19 and this is especially true in radiotherapy, in
which even small deviations from standards can have a large
negative impact on treatment quality and outcomes. The ben-
efits of using quality indicators to assess adherence to clinical
protocols was recently demonstrated by Cheng et al.9 Those
authors evaluated 10 quality indicators to measure the qual-
ity of care in 1378 breast cancer patients. They found that
most patients received good care (defined as reasonably good
adherence to the quality indicators); however, they also found
that 100% adherence to the entire set of quality indicators
was significantly associated with better overall survival. This
finding underscores the crucial importance of strict adher-
ence to established clinical protocols; moreover, this result
also demonstrates the value of performing a clinical audit to
assess compliance: without a clinical audit, it is not possible
to assess adherence. As the authors of that study conclude,
“100% adherence to evidence supported quality-of-care indi-
cators is associated with better survival rates and should be a
priority for practitioners”.
In recent years, there has been a surge in interest in quality
control in radiotherapy. As Donaldson et al.12 recently wrote,
all health care practitioners share the goal of conducting “best
practice” medicine but the obstacles to doing so are enormous
given the vast amount of quality standards, guidelines, rec-
ommendations, and indicators currently available. For these
reasons, Donaldson and colleagues argue that we  need to
identify the essential dimensions of quality. However, it can
be challenging to select the appropriate indicators of quality,
particularly given the wide range of procedures, processes and
techniques in radiotherapy; moreover, treatment varies widely
depending on the cancer type and location. Consequently, it
is not possible to evaluate, for example, prostate cancer and
rectal cancer, in exactly the same way. In other words, specific
indicators are necessary, which is what we are attempting to
develop with the IROCA project.
At the time of drafting this manuscript, we have not yet
begun the IROCA pilot study; however, we  believe that the
groundwork laid thus far will be immensely valuable, not
only for the current project but also for future clinical audits
to be performed by other institutions. Importantly, in line
with the study aims, we have developed detailed question-
naires that evaluate most (if not all) of the key aspects within
























































reports of practical oncology and 
reatment efficiency. In addition, we have identified and
elected (by expert group consensus) the most relevant indi-
ators to measure these key aspects. The selection of quality
ndicators in radiotherapy has been keenly debated in recent
ears.3,20 In prostate radiotherapy, several groups have devel-
ped quality indicators6–8 although it should be noted that
any of these indicators have not yet been validated.
.  Conclusions
lthough identification and selection of the most relevant
uality indicators is essential, the design and implementa-
ion of the clinical audit is equally if not more  important.
ur experience with the previous audit has demonstrated the
mportance of establishing well-defined procedures for the
linical audit. In addition, we have learned that the selection
nd components of the audit team are critical to guarantee an
nbiased audit. When this audit is completed, members of our
roup will have completed three separate radiotherapy audits:
) the initial WCO/ICO audit2, 2) the local audit performed by
he ICO at its three centres, and 3) this multinational, multi-
entre audit involving five cancer care centres across Europe
rom Portugal to Poland. The experience gained in this project
ill provide knowledge that will be transferrable to other cen-
res wishing to perform a similar clinical audit.
The primary value of this project is that it represents a
tep towards increased harmonization of radiotherapy pro-
esses among five large European radiotherapy departments.
lthough we  do not expect to immediately unify all aspects
f diagnosis, treatment, and follow up at these centres, we do
elieve that—upon completion of the project—we will have
chieved a much more  detailed understanding and appreci-
tion for the need to compare clinical practice at the home
nstitution to the practices observed at the audited institu-
ions.
There is an inexorable and growing interest in improv-
ng quality control in radiotherapy and the role of clinical
udits can only grow. The value of the present study is
hat the auditing protocol and quality indicators developed
ere to assess rectal and prostate cancer can be adapted
o improve treatment of other tumour localizations at other
adiotherapy centres worldwide. Although clinical audits are
ime-consuming and complex undertakings, the potential
enefits in terms of identifying and rectifying deficiencies in
uality control procedures are potentially enormous. External
linical audits can undoubtedly improve both patient safety
nd quality of care.
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